While anti-VEGF therapies remain the current standard of care, many DME patients experience suboptimal responses due to ...

GLP-1 receptor agonists and fenofibrate medications significantly reduced the risk for developing diabetic macular edema, ...

Please provide your email address to receive an email when new articles are posted on . “This is a really exciting new mechanism of action for our field, hoping to improve functional as well as ...

DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New ...

EyePoint (EYPT) announced details for its pivotal Phase 3 program evaluating Duravyu for the treatment of diabetic macular edema with first ...

At the 131st Congress of the French Society of Ophthalmology in Paris, France, the role of second-generation intravitreal anti-VEGF injections compared to corticosteroid injections in treating ...

A study led by the University of Barcelona and the Biomedical Research Networking Center in Diabetes and Associated Metabolic Disorders (CIBERDEM) reveals how a new mechanism could improve the ...

In a recent study published in the journal Neurology, researchers assessed the genetic variation among targets of Alzheimer's disease risk and anti-diabetic drugs. Study: Genetic Variation in Targets ...

DelveInsight’s, “Diabetic Nephropathy Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Nephropathy pipeline landscape. It covers ...